• Explore /
  • Poster
  • / Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.

Patient-reported outcomes (PROs) from MARIANNE: A phase III study of trastuzumab emtansine (T-DM1) +/- pertuzumab (P) vs trastuzumab + taxane (HT) for HER2-positive advanced breast cancer.

Abstract Poster

Authors

Carlos Barrios

Carlos H. Barrios

PUCRS School of Medicine, Porto Alegre, Brazil

Carlos H. Barrios , David Cella , Miguel Martin , Wolfgang Eiermann , Howard A. Burris III, Young-Hyuck Im , Pier Franco Conte , Masakazu Toi , Tadeusz Pienkowski , Xavier B. Pivot , Benjamin Beckermann , Sven Franz Stanzel , Jennifer Petersen , Paul Anthony Ellis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

HER2+

Clinical Trial Registration Number

NCT01120184

Citation

J Clin Oncol 34, 2016 (suppl; abstr 593)

DOI

10.1200/JCO.2016.34.15_suppl.593

Abstract #

593

Poster Bd #

81

Abstract Disclosures

Similar Posters

First Author: Akihiko Shimomura

First Author: Karen Bartley

First Author: WanChen Hsieh

First Author: Veronique Debien